Lynda M. Dee Honored with Partnership Award for Tireless Work in Advancing Access to Life-Saving Treatment for People Living with HIV and Hepatitis

FOR IMMEDIATE RELEASE: June 7, 2013
Contact: Meico Whitlock, 202-434-8094, www.NASTAD.org

Lynda Dee

Left to right: Murray Penner, NASTAD Deputy Executive Director and Lynda M. Dee

Washington, DC – The National Alliance of State and Territorial AIDS Directors (NASTAD) recognized Lynda M. Dee with a Partnership Award at its 22nd Annual Meeting of state health department HIV and hepatitis program leaders last month. The meeting takes place every May in Washington, D.C. Ms. Dee is a founder of AIDS Action Baltimore (AAB), a non-profit organization dedicated to the support and education of people with HIV and the prevention of HIV. AAB provides educational, financial, and emotional support for people with HIV and HIV prevention services in the Baltimore metropolitan area. Ms. Dee is also a licensed attorney in Maryland and assists people living with HIV with legal issues.“Lynda is a dear friend and colleague who has been instrumental in not only helping to ensure that new drugs continue to be developed, but also that people living with HIV and hepatitis have access to these life-saving treatments,” noted NASTAD Deputy Executive Director Murray Penner. “Without her work in the HIV and hepatitis world, the treatment landscape would be much different. She’s a critical partner of NASTAD’s in helping us continue to achieve a world free of HIV and hepatitis.”

Ms. Dee worked with Martin Delaney and other activists in the early days of treatment advances through the Fair Pricing Coalition, the AIDS Treatment Activist Coalition, the AIDS Clinical Trials Group and many other organizations to ensure dialogue and partnerships with pharmaceutical manufacturers about development, pricing and access programs. She continues to be a tireless treatment advocate, working with academia, industry and government to expedite ethical drug development and to provide access to life-saving treatments, even before drug approval. She has been a member of various FDA Antiviral Drug Advisory approval panels, including both the first HIV and hepatitis C (HCV) Protease Inhibitor Hearings and has been a member of various NIH advisory boards. Among many other activities, she is co-chair of the Maryland Hepatitis Coalition and a longtime member of the Maryland State ADAP Formulary Advisory Committee.

-###-

The National Alliance of State & Territorial AIDS Directors (NASTAD), founded in 1992, is a nonprofit national association of state and territorial health department HIV/AIDS program directors who have programmatic responsibility for administering HIV/AIDS, viral hepatitis and associated public health programs. NASTAD works to strengthen the role and promote the success of state and territorial public health programs in the U.S. and internationally. For more information, visit www.NASTAD.org